Franklin Resources Inc. Boosts Holdings in Novo Nordisk A/S $NVO

Franklin Resources Inc. boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 4,190.8% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 13,984,789 shares of the company’s stock after purchasing an additional 13,658,867 shares during the period. Franklin Resources Inc. owned approximately 0.31% of Novo Nordisk A/S worth $776,016,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Van ECK Associates Corp lifted its holdings in shares of Novo Nordisk A/S by 18.0% in the 3rd quarter. Van ECK Associates Corp now owns 788,722 shares of the company’s stock valued at $43,766,000 after buying an additional 120,127 shares during the period. FourThought Financial Partners LLC boosted its stake in shares of Novo Nordisk A/S by 8.0% in the third quarter. FourThought Financial Partners LLC now owns 62,547 shares of the company’s stock worth $3,471,000 after buying an additional 4,613 shares during the last quarter. Claret Asset Management Corp grew its holdings in Novo Nordisk A/S by 376.5% during the third quarter. Claret Asset Management Corp now owns 144,998 shares of the company’s stock worth $8,046,000 after acquiring an additional 114,568 shares during the period. Winthrop Capital Management LLC grew its holdings in Novo Nordisk A/S by 19.2% during the third quarter. Winthrop Capital Management LLC now owns 4,602 shares of the company’s stock worth $255,000 after acquiring an additional 741 shares during the period. Finally, Capital International Inc. CA raised its position in Novo Nordisk A/S by 191.4% during the third quarter. Capital International Inc. CA now owns 233,578 shares of the company’s stock valued at $12,961,000 after acquiring an additional 153,428 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $38.73 on Wednesday. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 12-month low of $35.85 and a 12-month high of $82.57. The business’s 50 day moving average is $50.93 and its two-hundred day moving average is $52.11. The company has a market capitalization of $172.92 billion, a P/E ratio of 11.16 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is presently 23.63%.

Wall Street Analyst Weigh In

NVO has been the topic of several recent research reports. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Citigroup assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 27th. They issued a “neutral” rating for the company. Kepler Capital Markets downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, CICC Research began coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 price target on the stock. Four research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $49.93.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Capacity and production investment — Novo is expanding manufacturing in Ireland with ~ $506m to raise oral GLP‑1 output to meet global demand, which supports longer‑term volume growth and supply resilience. Novo expands manufacturing (InsiderMonkey)
• Positive Sentiment: Distribution partnership — Novo agreed to supply Wegovy/Ozempic through Hims & Hers’ telehealth platform, ending a legal dispute and opening a digital channel that could broaden U.S. access and sales. That deal helped calm one litigation front and may support volume. Novo-Hims deal (Reuters)
• Positive Sentiment: Share repurchase — Novo confirmed ongoing share buybacks (part of up to DKK15bn programme), which is supportive for shareholder returns and EPS. Share repurchase programme (GlobeNewswire)
• Neutral Sentiment: Past earnings vs. guidance — Novo beat Q4 consensus on revenue and EPS but earlier issued weak FY2026 guidance that pressured the stock; investors now weigh strong recent results against management’s cautious full‑year outlook. Q4 results & guidance (Seeking Alpha)
• Negative Sentiment: FDA warning letter — The U.S. FDA issued a warning letter after an inspection tied to Plainsboro (early 2025) citing failures in post‑marketing safety reporting for semaglutide products; the regulator flagged potential unreported adverse events including two deaths and a suicide — a material safety/regulatory risk that spooked investors. FDA warning (Reuters) Potential unreported side effects (Forbes)
• Negative Sentiment: Legal / investor risk — A law firm (Pomerantz) has launched an investigation on behalf of investors, increasing potential litigation/legal-cost overhangs. Investor investigation (GlobeNewswire)
• Negative Sentiment: Analyst downgrades and pipeline concerns — TD Cowen cut NVO to Hold and other analysts flagged the pipeline as “not poised to blunt semaglutide loss‑of‑exclusivity” and rising competitive pressure from new GLP‑1 entrants, pressuring forward expectations and valuation. Pipeline downgrade (Yahoo Finance)
• Negative Sentiment: Market reaction / sector weakness — Healthcare indices were weaker intraday as investors rotated away from GLP‑1 names amid safety/regulatory headlines and heightened competition; that broad sentiment hit NVO alongside the specific company news. Sector decline (Yahoo Finance)

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.